Meeting Banner
Abstract #0563

CM101: an optimized MR probe targeting type I collagen for detection of liver fibrosis

Christian T. Farrar1, Richard Kennan2, Eric Gale1, Ian Ramsay1,3, Ricard Masia4, Gunisha Arora5, Kailyn Looby5, Lan Wei5, Michelle Bunzel2, Chunlian Zhang2, Yonghua Zhu2, Taro Akiyama2, Michael Klimas2, Shirly Pinto2, Himashinie Diyabalanage3, Valerie Humblet3, Bryan C. Fuchs5, and Peter Caravan1

1Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United States, 2Merck Research Laboratories, Kenilworth, NJ, United States, 3Collagen Medical, Belmont, MA, United States, 4Pathology, Massachusetts General Hospital, Boston, MA, 5Surgical Oncology, Massachusetts General Hospital, Boston, MA, United States

Recent molecular MR approaches targeting collagen demonstrated the promise of noninvasive detection and staging of liver fibrosis and monitoring treatment response, but the molecular probe used was not suitable for clinical translation due to the low stability of the Gd chelator chosen. CM-101 is a new peptide based probe using the highly stable Gd-DOTA chelate that is rapidly eliminated from plasma intact into the urine and shows no sign of Gd accumulation. CM-101 robustly detected liver fibrosis in a bile duct ligation model in rats and in a CCl4 mouse model.

This abstract and the presentation materials are available to members only; a login is required.

Join Here